Following these results, FOENIX-CCA4 (NCT05727176), an open-label, multinational, phase II study, aims at confirming the clinical benefit of futibatinib and evaluating the safety and efficacy in previously treated CCA harboring FGFR2 gene fusions and other rearrangements. Here, FGFR2 is linked to cholangiocarcinoma.